This is from April 26th, 70% of workforce will be cut:
On Monday, Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. This comes only weeks after Bristol Myers Squibb abandoned its clinical collaboration program with Nektar on bladder cancer and renal cell carcinoma.
https://www.biospace.com/article/nektar-cuts-70-percent-of-workforce-reorganizes-after-unsuccessful-bms-collaboration/